Vinblastine Sulfate – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 67 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Medical guide Drugs (A - Z) Feb 8, 2026 26 reads
Related reading

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Vinblastine Sulfate is the sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties. Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04) Vinblastine sulfate appears as an anticancer drug. White to slightly yellow crystalline...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Vinblastine Sulfate is the sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties. Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04) Vinblastine sulfate appears as an anticancer drug. White to slightly yellow crystalline powder. (NTP, 1992) Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Mechanism of action The antitumor activity of vinblastine...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Use in Cancer in simple medical language.
  • This article explains Contraindications in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Vinblastine Sulfate is the sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties. Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)

Vinblastine sulfate appears as an anticancer drug. White to slightly yellow crystalline powder. (NTP, 1992) Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Mechanism of action

The antitumor activity of vinblastine is thought to be due primarily to the inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multi-ringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumor properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effects. The vinca alkaloids are considered to be cell cycle phase-specific.

Indications

  • For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin’s and non-Hodgkin’s lymphomas, mycosis fungoides, histiocytosis, and Kaposi’s sarcoma.
  • Autoimmune Hemolytic Anemia
  • Bladder Cancer, Cancer
  • Immune platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">Thrombocytopenia (ITP)
  • Kaposi’s sarcoma
  • Letterer-Siwe disease
  • Lymphoma, Hodgkins
  • Metastatic Melanoma
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Advanced Alibert-Bazin syndrome
  • Advanced Soft Tissue Sarcoma (STS)
  • Advanced Testicular cancer
  • Histiocytic lymphoma
  • Refractory Breast cancer

Use in Cancer

Vinblastine sulfate is approved as a palliative treatment for:

  • Breast cancer has not gotten better with other treatments. It is used in adults.
  • Choriocarcinoma (a type of gestational trophoblastic disease) has not gotten better with other chemotherapy. It is used in adults.
  • Hodgkin lymphoma. It is used in adults and children with advanced diseases.
  • Kaposi sarcoma. It is used in adults.
  • Mycosis fungoides (a type of cutaneous T-cell lymphoma). It is used in adults.
  • Non-Hodgkin lymphoma (NHL) in adults.
  • Testicular germ cell tumors. It is used in adults and children with advanced diseases.

Contraindications

  • Contraindications—hypersensitivity to drug or class, bacterial infection, granulocytopenia, intrathecal use, intestinal obstruction, paralytic ileus.
  • Vinblastine sulfate is contraindicated in patients who have significant granulocytopenia, in the presence of bacterial infection. Such infections must be brought under control prior to the initiation of therapy with vinblastine sulfate.

Dosage

Strengths: 10 mg; 1 mg/mL

Usual Adult Dose

Breast Cancer

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before the leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Kaposi’s Sarcoma

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before the leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Testicular Cancer

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Hodgkin’s Disease

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Mycosis Fungoides

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Choriocarcinoma

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Lymphoma

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Histiocytosis

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that the dose not be given more frequently than once every 7 days. The manufacturer outlines the following conservative incremental approach to dosage every 7 days for adults:

  • First dose: 3.7 mg/m2 IV
  • Second dose: 5.5 mg/m2 IV
  • Third dose: 7.4 mg/m2 IV
  • Fourth dose: 9.25 mg/m2 IV
  • Fifth dose: 11.1 mg/m2 IV
  • This progression may be followed up to a maximum dosage of 18.5 mg/m2 IV. The dose should not be increased after that dose which reduces the white cell count to approximately 3000 cells/mm3. In some adults, 3.7 mg/m2 IV may produce this leukopenia; other adults may require more than 11.1 mg/m2 IV; and, very rarely, as much as 18.5 mg/m2 IV may be necessary. For most adult patients, the weekly dose will be 5.5 to 7.4 mg/m2 IV.
  • When the dose which produces the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance so the patient is receiving the maximum dose that does not cause leukopenia. Even though 7 days have elapsed, the next dose should not be given until the white cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of subsequent doses.

Usual Pediatric Dose

Testicular Cancer

Initial doses of this drug in pediatric patients varies depending on the schedule used and whether it is administered as a single agent or incorporated within a chemotherapeutic regimen:

  • As a single agent for Letterer-Siwe disease (histiocytosis X), the initial dose is 6.5 mg/m2 IV
  • When used in combination with other chemotherapeutic agents for Hodgkin’s disease, the initial dose is 6 mg/m2 IV
  • For testicular germ cell carcinomas, the initial dose is 3 mg/m2 IV in a combination regimen
  • Dose modifications should be guided by hematologic tolerance.

Hodgkin’s Disease

Initial doses of this drug in pediatric patients varies depending on the schedule used and whether it is administered as a single agent or incorporated within a chemotherapeutic regimen:

  • As a single agent for Letterer-Siwe disease (histiocytosis X), the initial dose is 6.5 mg/m2 IV
  • When used in combination with other chemotherapeutic agents for Hodgkin’s disease, the initial dose is 6 mg/m2 IV
  • For testicular germ cell carcinomas, the initial dose is 3 mg/m2 IV in a combination regimen
  • Dose modifications should be guided by hematologic tolerance.

Histiocytosis

Initial doses of this drug in pediatric patients varies depending on the schedule used and whether it is administered as a single agent or incorporated within a chemotherapeutic regimen:

  • As a single agent for Letterer-Siwe disease (histiocytosis X), the initial dose is 6.5 mg/m2 IV
  • When used in combination with other chemotherapeutic agents for Hodgkin’s disease, the initial dose is 6 mg/m2 IV
  • For testicular germ cell carcinomas, the initial dose is 3 mg/m2 IV in a combination regimen
  • Dose modifications should be guided by hematologic tolerance.

Side effects

Most Common 

  • Most people do not experience all of the vinblastine side effects listed.
  • Vinblastine’s side effects are often predictable in terms of their onset and duration.
  • Vinblastine’s side effects should improve after treatment is complete.
  • Vinblastine’s side effects are usually quite manageable. There are many options to help minimize or prevent the side effects of vinblastine.
  • Low blood counts. Your white and red blood cells and platelets may temporarily decrease. This can put you at increased risk for infection, anemia and/or bleeding.
  • Injection site reactions
  • Fatigue, and weakness
  • Nausea and vomiting – usually moderate and occur within the first 24 hours of treatment
  • Poor appetite
  • Peripheral neuropathy (numbness in your fingers and toes) may occur with repeated doses. This should be reported to your healthcare provider.
  • Constipation may occur within 1-3 days after your treatment, and is sometimes accompanied by abdominal cramping. It is important to keep your bowels moving regularly.

More Common 

  • Diarrhea
  • Fever
  • Hair loss may occur, but your hair will most likely grow back when the treatments are completed. This usually begins 2-3 weeks after each treatment.
  • Hearing loss
  • Mouth sores
  • Taste changes, metallic taste
  • Headache
  • Depression
  • Jaw pain, bone pain, tumor pain
  • High blood pressure (hypertension)
  • Tiredness
  • Shortness of breath, myalgias (muscle pain), and arthralgias (joint pain) may occur infrequently

Rare

  • temporary mental depression,
  • paresthesias,
  • loss of deep tendon reflexes,
  • headache,
  • convulsions,
  • psychoses;
  • dysfunction of the autonomic nervous system, with marked constipation,
  • paralytic ileus,
  • urinary retention,
  • bilateral pain and tenderness of the parotid glands associated
  • dryness of the mouth, sinus tachycardia;
  • nausea, vomiting,
  • anorexia,
  • diarrhea;
  • loss of hair,
  • vesicular mucositis of the mouth, and
  • dermatitis. (NTP, 1992)

Drug Interactions

Pregnancy and Lactation

Pregnancy category D 

Vinblastine Sulfate During Pregnancy or Breastfeeding. Vinblastine Sulfate is not recommended for use during pregnancy. It may harm the fetus. If you become pregnant or think you may be pregnant, tell your doctor immediately. It is unknown if this drug passes into breast milk.
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It is probably impractical to resume breastfeeding after vinblastine therapy because of the drug’s long half-life. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breast milk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

Lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It is probably impractical to resume breastfeeding after vinblastine therapy because of the drug’s long half-life. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breast milk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

What special precautions should I follow?

Before receiving vinblastine,

  • tell your doctor and pharmacist if you are allergic to vinblastine, any other medications, or any of the ingredients in vinblastine injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: aprepitant (Emend), certain antifungals such as itraconazole (Sporanox) and ketoconazole (Nizoral); clarithromycin (Biaxin, in Prevpac); erythromycin (E.E.S., E-Mycin, others); HIV protease inhibitors including indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); phenytoin (Dilantin), tolterodine (Detrol, Detrol LA). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Tell your doctor and pharmacist about all the medications you are taking so they can check whether any of your medications may increase the risk that you will develop hearing problems during your treatment with vinblastine.
  • tell your doctor if you have an infection. Your doctor will want to treat your infection before you receive a vinblastine injection.
  • tell your doctor if you have or have ever had heart or blood vessel disease, including varicose veins (swelling, redness, or pain in a vein in your arms or legs), or lung or liver disease.
  • you should know that vinblastine may interfere with the normal menstrual cycle (period) in women and may temporarily or permanently stop sperm production in men. Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving vinblastine injections. If you become pregnant while receiving a vinblastine injection, call your doctor. Vinblastine may harm the fetus.

When to contact your doctor or health care provider:

  • Severe constipation, unrelieved by laxative use
  • Nausea (interferes with the ability to eat and is unrelieved with prescribed medications)
  • Vomiting (vomiting more than 4-5 times in a 24-hour period
  • Diarrhea (4-6 episodes in a 24-hour period)
  • Unusual bleeding or bruising
  • Black or tarry stools, or blood in your stools
  • Blood in the urine
  • Pain or burning with urination
  • Extreme fatigue (unable to carry on self-care activities) Mouth sores (painful redness, swelling or ulcers)

Always inform your healthcare provider if you experience any unusual symptoms.

Precautions:

  • Before starting vinblastine treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
  • Do not receive any kind of immunization or vaccination without your doctor’s approval while taking vinblastine.
  • Inform your healthcare professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (vinblastine may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus).
  • For both men and women: Do not conceive a child (get pregnant) while taking vinblastine. Barrier methods of contraception, such as condoms, are recommended. Discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
  • Do not breastfeed while taking this medication.

Self-Care Tips

  • Apply a warm compress if you have any pain, redness, or swelling at the IV site, and notify your doctor.
  • Keep your bowels moving. Your healthcare provider may prescribe a stool softener to help prevent constipation that may be caused by this medicine.
  • If you experience diarrhea of greater than 4-6 stools per day, contact your healthcare provider and increase your fluid intake.
  • Drink at least 2 to 3 quarts of fluid every 24 hours, unless you were told to restrict your fluid intake, and maintain good nutrition. This will decrease your chances of being constipated, and prevent dehydration.
  • You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your healthcare provider.
  • Wash your hands often.
  • Use an electric razor and soft toothbrush to minimize bleeding.
  • Avoid contact sports or activities that could cause injury.
  • Avoid sun exposure. Wear SPF 30 (or higher) sunblock and protective clothing.
  • To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.
  • Follow the regimen of anti-diarrhea medication as prescribed by your health care professional.
  • Eat foods that may help reduce diarrhea
  • To help treat/prevent mouth sores, use a soft toothbrush, and rinse at least three times a day with 1/2 to 1 teaspoon of baking soda and/or salt in 8 ounces of water.
  • In general, drinking alcoholic beverages should be minimized or avoided. You should discuss this with your doctor.
  • Get plenty of rest
  • Maintain good nutrition
  • Remain active as you are able. Gentle exercise is encouraged such as daily walks
  • Use caution when driving or engaging in tasks that require alertness until a response to the drug is known.
  • If you experience symptoms or side effects, be sure to discuss them with your healthcare team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Vinblastine-sulfate
  2. https://pubchem.ncbi.nlm.nih.gov/compound/Vinblastine-sulfate-salt
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Vincaleukoblastine-sulfate
  4. https://medlineplus.gov/druginfo/meds/a682848.html
  5. https://go.drugbank.com/drugs/DB00570
  6. https://www.drugs.com/monograph/vinblastine.html
  7. https://www.cancer.gov/about-cancer/treatment/drugs/vinblastinesulfate
  8. CAMEO Chemicals
    LICENSE
    CAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data.
    https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false
    VINBLASTINE SULFATE
    https://cameochemicals.noaa.gov/chemical/21219
    CAMEO Chemical Reactivity Classification
    https://cameochemicals.noaa.gov/browse/react
  9. CAS Common Chemistry
    LICENSE
    The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
    https://creativecommons.org/licenses/by-nc/4.0/
    Vinblastine sulfate
    https://commonchemistry.cas.org/detail?cas_rn=143-67-9
  10. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Vinblastine sulfate [USAN:USP:JAN]
    https://chem.nlm.nih.gov/chemidplus/sid/0000143679
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  11. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Vinblastine sulfate
    https://comptox.epa.gov/dashboard/DTXSID601017133
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  12. European Chemicals Agency (ECHA)
    LICENSE
    Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: “Source: European Chemicals Agency, http://echa.europa.eu/”. Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
    https://echa.europa.eu/web/guest/legal-notice
    Vinblastine sulphate
    https://echa.europa.eu/substance-information/-/substanceinfo/100.005.097
    Vinblastine sulphate
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/134758
  13. NCI Thesaurus (NCIt)
    LICENSE
    Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C931
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  14. CCSbase
    VINBLASTINE SULFATE
    CCSbase Classification
    https://ccsbase.net/
  15. ChEMBL
    LICENSE
    Access to the web interface of ChEMBL is made under the EBI’s Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL378544/
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  16. Drug Gene Interaction database (DGIdb)
    LICENSE
    The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/VINBLASTINE SULFATE
  17. ClinicalTrials.gov
    LICENSE
    The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  18. DailyMed
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    VINBLASTINE SULFATE
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=VINBLASTINE+SULFATE
  19. Drugs and Lactation Database (LactMed)
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Vinblastine
    https://www.ncbi.nlm.nih.gov/books/NBK500696/
  20. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  21. FDA Orange Book
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  22. FDA/SPL Indexing Data
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    N00W22YO2B
    https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/
  23. International Agency for Research on Cancer (IARC)
    LICENSE
    Materials made available by IARC/WHO enjoy copyright protection under the Berne Convention for the Protection of Literature and Artistic Works, under other international conventions, and under national laws on copyright and neighbouring rights. IARC exercises copyright over its Materials to make sure that they are used in accordance with the Agency’s principles. All rights are reserved.
    https://publications.iarc.fr/Terms-Of-Use
    Vinblastine sulfate
    https://monographs.iarc.who.int/list-of-classifications
    IARC Classification
    https://www.iarc.fr/
  24. MassBank of North America (MoNA)
    LICENSE
    The content of the MoNA database is licensed under CC BY 4.0.
    https://mona.fiehnlab.ucdavis.edu/documentation/license
    VINBLASTINE SULFATE
    https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22KDQAABAKXDWYSZ-PNYVAJAMSA-N%22%27
  25. National Drug Code (NDC) Directory
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    VINBLASTINE SULFATE
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  26. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Vinblastine Sulfate
    https://www.cancer.gov/about-cancer/treatment/drugs/vinblastinesulfate
  27. NLM RxNorm Terminology
    LICENSE
    The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/11199
  28. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  29. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=64072649-101309878
  30. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    vinblastine sulfate
    https://www.wikidata.org/wiki/Q27077057
  31. Medical Subject Headings (MeSH)
    LICENSE
    Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.
    https://www.nlm.nih.gov/copyright.html
    Vinblastine
    https://www.ncbi.nlm.nih.gov/mesh/68014747
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Tubulin Modulators
    https://www.ncbi.nlm.nih.gov/mesh/68050257
    Antineoplastic Agents, Phytogenic
    https://www.ncbi.nlm.nih.gov/mesh/68000972
  32. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    GHS Classification Tree
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  33. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  34. PATENTSCOPE (WIPO)
    SID 388325377
    https://pubchem.ncbi.nlm.nih.gov/substance/388325377

 

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

Carbapenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Vinblastine Sulfate – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

A global war against illness

Help this medical guide reach someone who may need it

Share reliable health information with a patient, family member, caregiver, or colleague. Reading and awareness can help people ask better questions and seek appropriate care.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)